Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapsefree survival, and contamination by lymphoma cells using molecular analysis of immunoglobulin gene rearrangements. Forty-four patients with either NHL or HD underwent autologous transplantation after highdose chemotherapy. Patients were randomized to receive either Filgrastim-mobilized PBPC (n = 15) or unstimulated BM (n = 14). An additional 15 patients received PBPC without randomization because of a recent history of marrow involvement by lymphoma. Use of PBPC was associated with faster neutrophil engraftment than BM (11 vs 14 days to an absolute neutrophil count Ͼ0.5 × 10 9 /l, P = 0.04), but without any difference in platelet engraftment, infectious complications, or overall or event-free survival. Both BM (65%) and PBPC (73%) were frequently contaminated by tumor cells as assessed by CDR3 analysis. Patients with negative polymerase chain reaction analysis of a BM sample during the study had a trend towards an improved survival; however, BM involvement by disease had no impact on the ability to mobilize or collect PBPC. We conclude that PBPC are as effective as BM in reconstituting hematopoiesis after high-dose chemotherapy and that both products are frequently contaminated by sequences marking the malignant clone.
remissions in certain groups of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). [1] [2] [3] [4] [5] [6] [7] Autologous bone marrow (BM) transplantation has largely been replaced by peripheral blood progenitor cells (PBPC) that can be collected in the steady-state or mobilized with chemotherapy and/or colony-stimulating factors. There has been a marked increase in the use of PBPC as the sole hematopoietic support and there have been well-controlled clinical trials in which BM and PBPC support have been compared in a prospective fashion. [8] [9] [10] [11] However, the issue of potential tumor contamination in the infused product and possible contribution to relapse has not been well studied in BM and PBPC for patients with intermediate-grade NHL.
Analysis of minimal residual disease in patients with NHL has been reported using both immunologic and molecular-based techniques. The use of the polymerase chain reaction (PCR) assay with primers to the framework 3 region (CDR3) and J chain of the immunoglobulin heavy chain gene to detect minimal residual disease has been reported for both multiple myeloma and NHL. [12] [13] [14] In addition, rearrangement of the bcl-2 gene has been used in the analysis of low-grade follicular lymphomas. [15] [16] [17] Studies in leukemia have demonstrated that minimal numbers of malignant cells in the infused hematopoietic product can contribute to relapse. 18 Given the potential contribution of the contaminated product to relapse, it is important that possible differences in tumor contamination in BM and PBPC are analyzed.
We report a small, prospective, randomized trial of autologous BM vs PBPC as the sole hematopoietic support after high-dose chemotherapy for patients with relapsed NHL or HD. In addition to analyzing differences in engraftment, time to treatment failure, and resource utilization, we also conducted an analysis of tumor sequence contamination in the collected product using a PCR-based analysis of the CDR3 region of the immunoglobulin heavy chain gene.
We demonstrated that the choice of stem cell product resulted in minimal differences in engraftment, relapse and overall survival, and that both BM and PBPC were frequently contaminated by monoclonal tumor-specific sequences.
Patients and methods

Patients
The study protocol was reviewed by the Institutional Review Board and all patients gave written informed consent before study enrollment. Between April 1993 and June 1996, 47 sequential patients with either NHL or HD were accepted for autologous transplantation after review of pathological material and staging evaluation. Patients were evaluated by CT scans and bone marrow aspiration and biopsy for staging of their disease, and were classified by the International Working Formulation Project 19 and staged by the Ann Arbor system. 20 Standard pretransplant criteria were used to assess renal, hepatic, and cardiopulmonary function. 21 
Study design
Patients with a history of documented BM involvement by lymphoma or HD at any time in their disease course were assigned to receive PBPC as the sole hematopoietic support (n = 16) based on a presumed lower chance of malignant contamination. All other patients were randomized to receive either PBPC (n = 17) or autologous BM (n = 14) as the sole hematopoietic support. All PBPC were collected by large-volume leukapheresis by central or peripheral access 22, 23 to achieve 1 × 10 9 mononuclear cells/kg after Filgrastim (5 g/kg/day × 4 days). Patients randomized to receive autologous BM had marrow harvested from the posterior iliac crests under regional or general anesthesia, with a minimum 1.5 × 10 8 mononuclear cells/kg harvested. All patients received Filgrastim 5 g/kg/day, either s.c. or intravenously (i.v.) after hematopoietic infusion, and until an absolute neutrophil count (ANC) Ͼ1.0 × 10 9 /l for 3 consecutive days.
Patients stayed in a HEPA-filter isolation room after placement of a triple-lumen Hickman catheter. Chemotherapy consisted of thiotepa 300 mg/m 2 i.v. over 2 h × 1 day (total dose 300 mg/m . Prophylaxis for hemorrhagic cystitis consisted of hyperhydration (3000 ml/m 2 , i.v. daily) and bladder irrigation or i.v. Mesna at 100% the cyclophosphamide dose. Electrocardiograms and creatinine phosphokinase (CPK) measurements were done twice daily during cyclophosphamide administration. Thirty-six hours after completion of etoposide, autologous BM or PBPC were rapidly thawed at the bedside and infused via the central catheter. Ciprofloxacin 500 mg orally (p.o.) twice a day was administered from day −7 until engraftment, and trimethoprim-sulfamethoxisole (one double-strength tablet p.o. three times a week) was administered from time of engraftment until day 100. Filgrastim 5 g/kg/day either s.c. or by i.v. infusion was administered 4 h after stem cell infusion in all patients and was continued until ANC Ͼ1.0 × 10 9 /l was reached for 3 consecutive days. To help determine if mobilization of the PBPC by Filgrastim contributed to the high percentage of PBPC contamination, we collected the buffy coat from 1 unit of whole blood donated the day before Filgrastim administration for PCR analysis, and this was compared with the PBPC collected 5 days later.
Study endpoints and definitions
The primary endpoints of this study were to compare the number of days to neutrophil and platelet engraftment in patients randomized to either PBPC or bone marrow infusion. The time to neutrophil engraftment was defined as the number of days following infusion of hematopoietic support to achieve an ANC of Ͼ0.5 × 10 9 /l. The time to platelet engraftment was defined as the number of days following infusion of hematopoietic support to achieve a platelet count of Ͼ20 × 10 9 /l independent of a platelet transfusion for 3 days (first of 3 days). This definition was chosen to ensure that the endpoint accurately reflected sustained engraftment of platelets.
The secondary endpoints included a comparison of the number of hospital days in the treatment groups. The definition of hospital stay was the number of days from admission for chemotherapy to the date of discharge. Additional secondary endpoints included a comparison of overall and event-free survival in the treatment groups and the frequency of tumor sequence (CDR3) detection in either PBPC or bone marrow.
Transplant-related mortality is defined as death from causes other than progression of underlying disease and during the period of time from hematopoietic cell infusion to complete engraftment.
Histologic evidence for bone marrow involvement by lymphoma was defined as any evidence of tumor in the marrow using standard light microscopy. No patients were excluded on the basis of marrow involvement.
Laboratory studies
All patients with NHL participated in a laboratory-based companion trial designed to determine the frequency of contamination of BM and PBPC by occult lymphoma cells using molecular-based techniques. A sample of BM aspirate was obtained for molecular analysis in all patients at the time of study registration, as was a sample of the PBPC harvest, and follow-up samples of BM were obtained for histologic and molecular analysis at 100 and 300 days after stem cell infusion. In 11 patients undergoing PBPC collection, a unit of whole blood was collected immediately before initiating Filgrastim for PBPC mobilization. A buffy coat was prepared for PCR analysis, and was compared with a sample of PBPC collected several days after mobilization.
Molecular analysis for minimal residual disease was based on detection of clonal CDR3 regions from the immunoglobulin heavy chain gene unique for a patient's tumor and detected using tumor-specific oligonucleotide PCR.
14 Alternate molecular PCR-based markers (T cell receptor ␤ and bcl-2) were used when CDR3 analysis was nondiagnostic. The nucleotide sequence of primers used in PCR analysis are given in Table 1 .
DNA extraction
Paraffin-embedded blocks or frozen tissue of each patient's diagnostic lymph node biopsy were obtained. Paraffinembedded tissue sections (3 × 7 microns) were extracted using standard methods of xylene extraction, alcohol washing, and drying. 24 The extracted tissue was digested with proteinase K in 100 g/ml digestion buffer (50 mm Tris pH 7.5, 1 mm EDTA, 0.5% Tween-20) overnight at 37°C. Proteinase K inactivation was done at 80°C for 10 min. The lymph node extract was then used directly for PCR.
Mononuclear cells were separated from BM, whole blood, or PBPC by Ficoll density gradient centrifugation. DNA was isolated by treating the cells with sodium dodecyl sulfate (SDS) and proteinase K, followed by pheno/ chloroform extraction and ethanol precipitation. Frozen samples were mechanically ground and placed in digestive buffer with proteinase K as with paraffin samples.
Consensus PCR and identification of a tumor-specific CDR3
CDR3 DNA regions present in the extracted lymph node DNA were amplified by PCR using VH framework 3 consensus (5Ј-ACACGGCTGTGTATTACTGT-3Ј) 24 and JH consensus (5Ј-AACTGCAGAGGAGACGGTGACC-3Ј) primers. 25 The reaction mixture consisted of genomic DNA (0.5-1 g); VH consensus and JH consensus primers (80 pmol); Taq polymerase (0.5 l; Promega, Madison, WI, USA); 10× buffer (10 ml; Promega); and 25 mm MgCl 2 (5 l); dGTP, dATP, dCTP and dTTP (0.25 mm each, Pharmacia, Piscataway, NJ, USA) in a total volume of 100 l; with a mineral oil overlay. In each round, an initial denaturation step at 95°C for 7 min preceded the addition of enzymes. PCR was performed for 35-40 cycles using a Perkin Elmer Cetus Thermocycler (Emeryville, CA, USA) (denaturation at 95°C for 75 s, annealing at 58°C for 75 s, and extension at 72°C for 90 s with a final extension of 6 min). Samples that were negative for tumor-specific CDR3 by initial screening using framework 3 primers underwent an additional PCR reaction using a framework 2 VH primer (5Ј-TGGGTCCGACAGGCTCCNGG-3Ј). 26 First-round PCR was performed as above with framework 2 VH primer and JH consensus primer (LJH) for 30 cycles (annealing at 50°C) followed by a second 22 rounds of PCR using 1 l from the product of the first 30 cycles with framework 2 VH primer and JH consensus primer (VLJH).
The PCR products were separated and visualized on 2% agarose gels using ethidium bromide. DNA from the consensus PCR was cloned into the TA vector pCR-TM II Table 1 Nucleotide sequence of primers used in PCR reactions (Invitrogen, Carlsbad, CA, USA). Sequencing of purified double-stranded plasmid DNA was performed according to the dideoxy chain termination method by using Sequenase Version 2 DNA Polymerase (USB Sequencing, Cleveland, OH, USA). 14 Reaction products were visualized on 8% denaturing polyacrylamide gels. Between eight and 16 amplified and cloned CDR3 DNA sequences from each sample were sequenced, and a predominate clone was identified. The predominate tumor CDR3 was aligned to known immunoglobulin heavy chain sequences using GenBank. Sequences within the CDR3 that corresponded to the highly variable junctional region between V and D were identified, and a corresponding tumor-specific oligonucleotide (TSO) was commercially constructed 14 (Oligos Etc, Guilford, CT, USA).
Patients with T cell NHL had a predominant tumor clone identified by PCR amplification of the ␤-chain T cell receptor-gene rearrangement. The ␤ receptor-gene rearrangement was amplified from the lymph node DNA using a DBlprimer (5Ј-CAAAGCTGTAACATTGTGGGGAC-3Ј) and a JB2 primer (5Ј-AGCAC(T/G/C)GTGAGCC(T/G) GGTGCC-3Ј). 25 Forty cycles at conditions identical to the CDR3 amplification were used to amplify the ␤ chain rearrangement.
TSO-PCR
Semi-nested PCR using V and J consensus primers and TSO and J consensus primers were used to detect the presence of minimal tumor contamination in BM, whole blood, and PBPC of each patient with an identified clonal CDR3. Genomic DNA (0.5-1.0 g) was added to each PCR tube. The first round of amplification included 30-35 cycles under conditions described above. A 0.01 to 1.0 l aliquot of the PCR product was reamplified for 20-25 cycles using the TSO and J consensus primer. Cycling conditions varied depending on the tumor and specificity of the TSO. TSO-PCR was also performed in an analogous manner on samples from a patient with a T cell NHL.
bcl-2/J H Ig PCR
Lymph node DNA that did not have a predominant CDR3 rearrangement was PCR amplified using the bcl-2 sense (5Ј-GTTTGACCTTTAGAGAGTTGC-3Ј) and JH antisense (5Ј-ACCTGAGGAGACGGTGACC-3Ј) primers as described previously. 27, 28 Patients whose diagnostic tumor tissue showed a bcl-2/JH rearrangement had BM, whole blood, and PBPC analyzed for tumor contamination using this marker.
Controls and sensitivity
All PCR experiments were performed with appropriate negative and positive controls, including normal lymphoid or marrow DNA and lymphoid DNA with previously identified tumor clones. Sample contamination was avoided by receiving and processing all samples in a separate work place. All samples were processed using designated lab instruments and plugged pipettes. The sensitivity of CDR3 analysis was determined to be 1 in 10 5 cells via log dilutions of positive control DNA in normal DNA.
Statistical methods
Survival and event-free survival curves were estimated by Kaplan and Meier analysis 29 with log rank test for a difference in curves. Engraftment variables were compared using Student's t-test at the 5% significance level. Patient characteristics were compared using t-test, Fishers and Chi square analysis. All patients were restaged by CT scans on day 100 and then every 3 months for the first year after the transplant, and then every 6 months for the subsequent years. Additional testing, including BM aspiration and biopsy, was performed at 3 and 6 months after transplant and whenever clinically indicated. Complete response was defined as no evidence of disease by CT scans or physical examination or no change in abnormalities Ͻ2 cm over a 6 month period of time; partial remission was defined as a Ͼ50% decrease in the sum of the products of all measurable lesions; the progressive disease was defined as a Ͼ25% increase in any pre-existing tumor or the appearance of any new lesions, all determined at the 100 and 300 day evaluation.
Results
Patient characteristics
Forty-seven patients with HD (n = 12) or NHL (n = 35) were entered on study and were eligible for treatment. Three patients did not proceed to transplant because of hepatitis C infection (n = 1) or progressive disease (n = 2) and were excluded from survival analysis. Forty-four patients proceeded to transplant as assigned, 31 of whom had no history of histologic marrow involvement with their disease at any time in their disease history and were randomized to either BM (n = 14) or PBPC (n = 17) support. An additional 16 patients with a history of histologic BM involvement by their disease (n = 5) or marrow involvement at the time of registration (n = 11) were assigned to PBPC support based on the presumption that PBPC were less likely to be contaminated with tumor than marrow would be.
There were 27 women and 20 men entered on the protocol from April 1993 to June 1996, ages ranging from 19 to 67 years (mean, 46) ( Table 2 ). There were no statistically significant differences among the randomized patients; however, it should be noted that 50% of patients randomized to receive PBPC had HD, compared with 25% of patients randomized to receive BM (P = 0.25, Fisher's test). The percentage of patients who were classified as chemoresistant also varied: 53% of patients randomized to receive PBPC, 43% of patients randomized to receive BM, and 12% of patients assigned to receive PBPC (P = 0.67, Fisher's test). Median follow-up was 33 months for the BM group, 22 months for the randomized PBPC group, and 27 months for the assigned PBPC group. + cells/kg in the patients assigned to PBPC (P = 0.296). There were no statistical differences in the number of mononuclear cells mobilized, the number of collections, or the total volume processed in the randomized or assigned PBPC groups.
Engraftment
The engraftment variables for the three groups of patients were analyzed. The median number of days to achieve an ANC Ͼ0.5 × 10 9 /l was 14 (11-31) days in the BM group; 11 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) days in the PBPC randomized group (P = 0.0477); and 10 (8-18) days in the PBPC assigned group. No statistically significant difference in neutrophil engraftment was noted in the two PBPC groups despite a history of marrow involvement. The median number of days reach a platelet count of Ͼ20 × 10 9 /l independent of transfusions for 3 days was 22.5 days (range, 14-211) in the BM group; 26 days (range, 7-81) in the PBPC randomized group (P = 0.232); and 17 days (range, 9-46) in the PBPC assigned group. No statistically significant difference in platelet engraftment was noted in the two PBPC groups despite a history of marrow involvement (P = 0.97), and no episodes of graft failure were noted. There was no statistically significant difference in the number of singledonor platelet transfusions (13.5 vs 12 units, P = 0.95) or packed red blood cell units (11 vs 11.5 units, P = 0.93) for patients randomized to BM compared with those randomized to PBPC. There was also no difference in the number of days of i.v. antibiotics in the BM and PBPC groups (18 vs 18.4 days).
Transplant toxicity and complications
The major toxicities for the three treatment groups were not significantly different and were similar to those previously reported for this transplant conditioning regimen. 30 In parti- 
Hospital utilization
The mean time to discharge was 26 days, 31 days and 29 days in the groups randomized to BM or PBPC or assigned to PBPC, respectively (P = 0.13). There was no difference in the number of days of i.v. antibiotic usage in any of the three cohorts of patients.
Outcome analysis
Overall probability of survival and event-free survival was analyzed for the entire group of patients randomized to either BM or PBPC or assigned to PBPC by Kaplan-Meier analysis with a median follow-up of 31 months. An additional analysis was performed only for patients with NHL (Figures 1a and b) . The probability of overall survival and event-free survival for the entire group was not statistically affected by the choice of hematopoietic rescue. In the analysis of the NHL patients, the probability of overall survival at 36 months was 60.6% in patients randomized to BM, 57.1% in patients randomized to PBPC, and 65.7% in patients assigned to PBPC (P = 0.63 by log rank analysis). The probability of event-free survival was 41.7% in the NHL patients randomized to BM, 25% in patients randomized to PBPC, and 58% in patients assigned to PBPC (P = 0.38 by log rank analysis). No statistically significant differences were noted in either overall survival or eventfree survival for the different stem cell choices in the NHL patients. The majority of relapses occurred within the first 12 months with only one relapse after 2 years (27 months). The majority of relapses occurred at sites of previous bulk disease.
Detection of minimal residual disease in BM vs PBPC
Successful PCR analysis was achieved in 85% of patients (n = 29) with NHL using tumor-specific probes to the immunoglobulin heavy chain gene (n = 15), the T cell ␤ receptor (n = 2), or the bcl-2 locus (n = 12) ( Tables 3 and  4 ). In the remainder (15%), analysis was not possible because of the inability to find a dominant clone. In patients with an adequate sample for analysis, the frequency of a positive PCR result in the on-study BM was 55% and 76% in the collected PBPC. In patients without any history of histologic BM involvement, the frequency of a positive PCR result in the on-study BM was 56% and 88% in the collected PBPC. In patients with histologic BM involvement at the time of transplant, the PCR was positive in 72% in both the BM and the PBPC samples. Two patients with active disease in the BM at the time of transplant had a negative PCR result in both the BM and the PBPC samples. Table 4A and B summarize and detail all the PCR data and Figure 2 demonstrates a typical result from PCR using tumor-specific oligonucleotide primers. The probability for overall survival at 40 months for NHL patients with a negative PCR in on-study BM was 84.6% compared with 41.0% for patients with a positive PCR in on-study BM (P = 0.08 by log rank analysis) and 40% event-free survival for both positive and negative PCR groups. Subset analysis examining PCR results in randomized NHL patients (excluding patients with overt marrow involvement at time of transplant) revealed an overall survival of 71.4% vs 45%, P = 0.48 (on-study BM PCR negative or positive) and a event-free survival of 50% vs 28.6%, P = 0.375 (on-study BM PCR negative or positive). The probability for survival at 40 months for patients with a negative PCR for PBPC was 40% compared with 65.3% for patients with a positive PCR for PBPC (P = 0.99) with an event-free survival of 40% vs 40% (P = 0.49) in the same groups. Detection of CDR3 sequences in the marrow at 100 and 300 days after transplant demonstrated an overall positive rate of 73% without correlation to overall or relapse-free survival. ABMT = autologous bone marrow transplantation; NHL = non-Hodgkin's lymphoma; BM = bone marrow; PBPC = peripheral blood progenitor cell transplantation; NA = not available.
Discussion
The goal of this prospective randomized trial was to compare hematopoietic support with BM and PBPC after highdose chemotherapy in patients with NHL and HD. Our study was designed so that patients with a history of either remote or current BM involvement were assigned to PBPC support in an attempt to decrease the chance of tumor infusion. All patients received an identical preparative regimen and all patients received their assigned treatments. Our study demonstrates that Filgrastim-mobilized PBPC were equivalent to BM support with respect to many variables and has an advantage only in neutrophil engraftment. This difference did not translate into a survival advantage for patients receiving PBPC support, nor did it result in a decrease in hospital utilization. In our study, the conditioning regimen was very intensive and was associated with a high degree of severe mucositis. Despite a decrease in the number of days to neutrophil engraftment, the extent and severity of the mucositis prevented early discharge in many patients and likely accounted for the observed lack of difference between the two groups. In conditioning regimens that are less intense, discharge may be dictated by the ANC, resulting in a decrease in the number of hospital days in PBPC recipients. In contrast to several of the reported randomized trials of PBPC vs BM we did not demonstrate any improvement in the rapidity of platelet engraftment. This difference may relate to a number of variables including the degree of prior treatment, the use of steady-state vs chemotherapy mobilized PBPC, and the intensity of the preparative regimen. [8] [9] [10] [11] In contrast to our findings, Schmitz and colleagues 9 noted a small but significant reduction in hospital stay, transfusions, and number of days to neutrophil and platelet engraftment in favor of PBPC in a similarly sized randomized trial of PBPC vs BM support after BEAM chemotherapy. Although survival and relapse were not study endpoints in the Schmitz trial they failed to observe any survival or relapse advantage for either group. Their study excluded patients with BM involvement. In a separate cost analysis of the Schmitz study, PBPC transplantation was associated with a 23% reduction in overall cost. 31 This difference was in large part due to a decrease in the number of days in the intensive care unit and a lack of prospectively established uniform discharge criteria. 32 ized PBPC over BM. In another study examining PBPC and BM support in patients with germ cell tumors, no significant difference in hospital days was also observed despite a small difference in engraftment variables. 8 Our study was also able to analyze differences in the ability to mobilize PBPC in patients with a history of or active BM involvement with disease compared with patients without BM involvement. We observed no differences in the number of mononuclear or CD34 + progenitor cells collected, and no differences in the time to engraftment or blood product use in these groups of patients. The advantage in neutrophil engraftment was equally observed in both PBPC groups. We conclude that patients with marrow involvement can be successfully mobilized for PBPC collection. We observed no difference in relapse-free or overall survival in patients without any history of marrow involvement compared with those with either active or remote disease involvement. Yan and colleagues 33 demonstrated a poorer outcome only for patients with extensive marrow involvement at diagnosis (Ͼ50% large cells in the marrow). None of our patients had extensive (Ͼ50%) BM involvement at the time of transplant.
We failed to observe a difference in either the overall or relapse-free survival in the three study groups. Relapse occurs either from disease not ablated by the conditioning regimen or because of clonogenic tumor cells infused with the stem cells. Data from leukemic patients receiving BM grafts transduced with a retroviral marker suggest that infused cells may contribute to relapse. 18 However, the pattern of relapse in areas of prior bulk disease point towards a failure of the ablative chemotherapy. Our study was designed to determine the frequency of graft contamination by malignant sequences using molecular-based markers. Previous studies in patients with follicular NHL have demonstrated that detection of the rearranged bcl-2/IgH genetic loci is a prognostic factor after transplantation. [15] [16] [17] In our study, the majority of the patients had intermediate or highgrade NHL, and were not likely to carry a bcl-2 translocation. We therefore used the clonal detection of the CDR3 region of the IgH heavy chain gene as a marker of occult disease.
14 Using this technique, we successfully isolated the dominant clonal IgH rearrangement in 85% of the samples and then prepared tumor-specific oligonucleotide primers to use in patient-specific PCR analysis.
Using these molecular detection techniques, we have shown that a very high percentage (67-88%) of the PBPC collected in patients with or without a history of BM involvement by disease is contaminated with clonal CDR3 sequences. This result is somewhat higher than that reported by other groups examining smaller cohorts of similar patients. 10, 34 The percentage of patients with a positive PCR result in the marrow was also high (56%) and increased to 72% if active disease was present in the marrow at the time of transplant. Two patients with focal marrow involvement had a negative PCR assay reflecting either a false negative result secondary to DNA degradation or tumor cells in the aspirate sample below the level of detection. It is important to note that these sequences do not necessarily detect clonogenic tumor cells.
To help determine if mobilization of the PBPC by Filgrastim contributed to the high percentage of PBPC contamination, we collected the buffy coat from 1 unit of whole blood donated the day before Filgrastim administration for PCR analysis, and this was compared with the PBPC collected 5 days later. In all patients tested (n = 7), there was 100% concordance between the buffy coat and PBPC analysis suggesting that PBPC contamination was not significantly affected by filgrastim mobilization. A quantitative analysis between the two products was not possible given the difference in the number of B cells present.
PCR analysis did reveal clonal CDR3 contamination in 56% of the patients without a history of BM involved by disease at any time in their disease course. This is significantly higher than the 5-30% reported rate of histologic involvement of the marrow by intermediate grade NHL 35 and suggests that microcontamination of BM may be present in a large number of these patients. We noted a trend towards improved overall and relapse-free survival in the patients with a negative PCR in on-study BM in the randomized cohort of patients (overall survival 71.4% vs 45% (P = 0.48); event-free survival 50% vs 28.6%, P = 0.375). This may translate into an important prognostic factor if confirmed in a larger series of patients.
Despite the high degree of contamination of the BM and PBPC by CDR3 sequences, we did not observe any significant differences in either overall survival or relapse. This may be related to the number of malignant cells contaminating the infusion product necessary for contribution to relapse (threshold phenomenon) or detection of sequences from nonviable cells. Quantitative PCR analysis may help distinguish between these hypotheses and is currently underway in this series of patients.
We conclude from this investigation that PBPC cells mobilized with Filgrastim are equivalent to BM as a source of hematopoietic reconstitution. Use of PBPC result in a decrease in the number of days of neutropenia which did not result in a meaningful difference in hospital utilization, cost, or overall survival. Contamination of both the BM and PBPC by malignant cells as determined by CDR3 analysis is frequent but does not clearly correlate with ultimate disease outcome at this time. Detection of marrow involvement by disease using PCR-based methods in patients with intermediate-grade NHL may be more common than determined by conventional methods and may correlate with disease outcome. Further studies are warranted to determine if a threshold of contamination correlates with disease relapse.
